Elan, IL&P help ISEQ make gain
The ISEQ gained 12.73 points this morning to stand at 6738.0 at 10.30am.
Elan made the morning’s biggest increase, up 30c (4.6%) to €6.90. The pharmaceutical and its partner Biogen Idec announced that they have submitted a license application for controversial multiple-sclerosis drug Tysabri to the USFDA.